Biotechnology News and Research RSS Feed - Biotechnology News and Research

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX, a clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced that it has dosed in New Zealand the first patient in a Phase IIb/III clinical trial of ABX203 which is taking place in several countries of the Asia-Pacific region. [More]
Study: Plant compounds can help prevent liver damage during menopause

Study: Plant compounds can help prevent liver damage during menopause

Women going through menopause often struggle with weight gain that results when their estrogen levels drop, and many turn to weight-loss supplements to help them shed those extra pounds. But those supplements may cause an accumulation of fat in the liver and a potentially life-threatening condition called non-alcoholic fatty liver disease. [More]
Researchers develop revolutionary approach to treat drug-resistant tumors

Researchers develop revolutionary approach to treat drug-resistant tumors

In greater than 90 percent of cases in which treatment for metastatic cancer fails, the reason is that the cancer is resistant to the drugs being used. To treat drug-resistant tumors, doctors typically use multiple drugs simultaneously, a practice called combination therapy. [More]
Garlic compound can help fight lung infections in people with cystic fibrosis

Garlic compound can help fight lung infections in people with cystic fibrosis

A chemical found in garlic can kill bacteria that cause life-threatening lung infections in people with cystic fibrosis, research suggests. [More]

Berthold Technologies introduces Biametrics GmbH as a new co-operation partner

Berthold Technologies proudly announces the recently established co-operation with their new partner Biametrics GmbH. [More]

Kuros Biosurgery granted U.S. patent for synthetic hydrogel technology

Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for sealant, orthobiologic and surgical wound indications, announced today that its patent application U.S.S.N 12/102,157 will issue today and has been assigned U.S. Patent No. 8,961,947. [More]

Roche, BioMed X partner to develop novel nanomaterial-based biosensors

Roche and BioMed X announced today that they have entered into a collaboration agreement to establish a research group focusing on the development of a novel sensor technology platform based on new nanomaterials such as graphene. [More]
Shire announces acquisition of Meritage Pharma

Shire announces acquisition of Meritage Pharma

Shire plc and Meritage Pharma, Inc. announced today that Shire has acquired Meritage, a privately-held company, for an upfront fee of $70 million and additional contingent payments based on the achievement of development and regulatory milestones. [More]
New study could lead to better remedies for insomnia, more effective anaesthetic drugs

New study could lead to better remedies for insomnia, more effective anaesthetic drugs

Scientists have discovered that switching on one area of the brain chemically can trigger a deep sleep. [More]
High ThroughputPARP in vivo Pharmacodynamic Assay

High ThroughputPARP in vivo Pharmacodynamic Assay

AMSBIO has introduced a unique High Throughput PARP in vivo Pharmacodynamic Assay that can be used to monitor the efficacy of poly-ADP-ribose polymerase (PARP) inhibitors on PAR formation in vivo; and to measure drug action on PARP in both in vivo and in vitro settings [More]
Mayo Clinic researchers identify molecule that lays groundwork for development of pancreatic cancer

Mayo Clinic researchers identify molecule that lays groundwork for development of pancreatic cancer

A research team led by investigators from Mayo Clinic's campus in Jacksonville, Florida, and the University of Oslo, Norway, have identified a molecule that pushes normal pancreatic cells to transform their shape, laying the groundwork for development of pancreatic cancer -- one of the most difficult tumors to treat. [More]
Palatin introduces clinical trial website in support of bremelanotide phase 3 study for FSD treatment

Palatin introduces clinical trial website in support of bremelanotide phase 3 study for FSD treatment

Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has launched a clinical trial website in support of its phase 3 reconnect study with bremelanotide for the treatment of female sexual dysfunction (FSD). [More]
Industrial Biotechnology presents insights on cellulose nanocrystal toxicity

Industrial Biotechnology presents insights on cellulose nanocrystal toxicity

Novel nanomaterials derived from cellulose have many promising industrial applications, are biobased and biodegradable, and can be produced at relatively low cost. Their potential toxicity--whether ingested, inhaled, on contact with the skin, or on exposure to cells within the body--is a topic of intense discussion, and the latest evidence and insights on cellulose nanocrystal toxicity are presented in a Review article in Industrial Biotechnology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. [More]
Targeted nanomedicines could help prevent heart attacks caused by atherosclerosis

Targeted nanomedicines could help prevent heart attacks caused by atherosclerosis

Nanometer-sized "drones" that deliver a special type of healing molecule to fat deposits in arteries could become a new way to prevent heart attacks caused by atherosclerosis, according to a study in pre-clinical models by scientists at Brigham and Women's Hospital and Columbia University Medical Center. [More]
Researchers report development of first 3D tissue-engineered system

Researchers report development of first 3D tissue-engineered system

A team led by researchers at Tufts University School of Engineering and the University of Pavia has reported development of the first three-dimensional tissue system that reproduces the complex structure and physiology of human bone marrow and successfully generates functional human platelets. [More]
Novasep selected to commercially biomanufacture Celladon's Mydicar API

Novasep selected to commercially biomanufacture Celladon's Mydicar API

Novasep, a leading supplier of services and technologies for the life sciences industry, today announces that it has entered into an agreement with Celladon, a clinical-stage biotechnology company. Novasep will prepare to supply the drug substance for MYDICAR®. [More]
Researchers assemble comprehensive map of human epigenome

Researchers assemble comprehensive map of human epigenome

Virtually every cell in the body carries an identical genome. But how is it possible that each of the body's 200 different types of specialized cells - in the heart, brain, bone, skin and elsewhere - develops from the same DNA instruction book? [More]
UCSD researchers make new attempt to develop malaria vaccine candidate

UCSD researchers make new attempt to develop malaria vaccine candidate

Researchers at University of California, San Diego School of Medicine used algae as a mini-factory to produce a malaria parasite protein. The algae-produced protein, paired with an immune-boosting cocktail suitable for use in humans, generated antibodies in mice that nearly eliminated mosquito infection by the malaria parasite. [More]
Lupin introduces new InspiraChamber VHC under strategic licensing agreement with InspiRX

Lupin introduces new InspiraChamber VHC under strategic licensing agreement with InspiRX

Pharma Major Lupin Limited announced today that its US subsidiary, Lupin Pharmaceuticals Inc. (collectively Lupin) has launched the all new InspiraChamber Anti-Static Valved Holding Chamber (VHC) under a strategic licensing agreement with the New Jersey based respiratory research and development company InspiRX Inc. [More]
Dance Biopharm announces completion of $9.5 million convertible note and warrants financing

Dance Biopharm announces completion of $9.5 million convertible note and warrants financing

Dance Biopharm Inc., a privately-held biotechnology company focused on the development of inhaled insulin products to treat diabetes, today announced the completion of a $9.5 million convertible note and warrants financing. [More]